ALTERITY THERAPEUTICS LTD
Business
Alterity Therapeutics Limited is a biopharmaceutical company developing therapies for neurodegenerative diseases. The lead drug candidate ATH434 targets α-synuclein accumulation and iron redistribution in the central nervous system, with potential in Parkinson's disease and Multiple System Atrophy. ATH434 has completed Phase 2 trials in MSA and holds FDA Fast Track and Orphan Drug designations. The company operates a discovery platform with over 1,000 proprietary compounds and a diversified patent portfolio covering iron chaperones and zinc ionophores.
Summary from 20-F filed 2025-08-29
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-12.15M |
| Total assets | $46.03M |
| Total liabilities | $3.62M |
| Stockholders' equity | — |
| Operating cash flow | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ALTERITY THERAPEUTICS LTD's CIK number?
ALTERITY THERAPEUTICS LTD's SEC CIK number is 0001131343 (1131343). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ALTERITY THERAPEUTICS LTD's SEC filings?
All of ALTERITY THERAPEUTICS LTD's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.